Found 9 clinical trials
Migraine
A Study to Investigate the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants with Episodic Migraine
- 0 views
- 01 Feb, 2022
- 1 location
Migraine
The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the prevention of migraine in participants with episodic migraine. The study duration will be
- 0 views
- 18 Apr, 2022
- 1 location
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine (REBUILD-1)
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary
- 214 views
- 19 Jun, 2022
- 72 locations
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine (REBUILD-2)
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary
- 0 views
- 27 Jun, 2022
- 76 locations
Galcanezumab for Vestibular Migraine
validated a patient reported outcome tool for VM called VM-PATHI (VM- Patient Assessment Tool and Handicap Inventory). Anecdotal evidence suggests that CGRP antagonists, such as Galcanezumab, may be
- 0 views
- 06 Apr, 2022
- 1 location
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine (CHALLENGE-MIG)
The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the prevention of migraine in participants with episodic migraine. The study duration will be
- 11 views
- 28 Jun, 2022
- 70 locations
Observational Study on the Efficacy Safety and Tolerability of GAlcanezumab in Real Life Migraine Patients in ITaly
Objective: To determine in real life the efficacy, safety and tolerability of galcanezumab in the prevention of high-frequency episodic migraine (HFEM) and chronic (CM) migraine. Design
- 0 views
- 25 Mar, 2021
- 1 location
CGRP Inhibition, Autonomic Function, and Migraine (CGRP-1)
The purpose of this clinical study is to better understand the function of the autonomic nervous system in patients with migraine. We aim to understand whether the autonomic functions change depending on the migraine status (i.e. whether they are between or during attacks) and whether the CGRP monoclonal antibody (mAb) …
- 0 views
- 24 Apr, 2022
- 1 location
BIOmarkers of MIGraine: a Proof of Concept Study Based on the Stratification of Responders to CGRP Monoclonal Antibodies
Migraine is the 2nd most disabling neurological disease. It affects 14.7% of the population (children and adults) of whom 80% are female. In the European Union, the total annual cost of migraine is of 111 billion euros. If not adequately treated, migraine can evolve into the more severe chronic form …
- 0 views
- 05 May, 2021
- 3 locations